Latest Breaking News On - Geron corporation nasdaq - Page 1 : comparemela.com

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status Durable and sustained red blood cell.

Johna scarlettDrug administrationExchange commissionGeron corporation nasdaqMalignant hematology departmentMoffitt cancer centerPatient support programGeron corporationChief executiveRami komrokjiVice chairConference callEastern timePrescribing informationMedication guidePrivate securities litigation reform act

Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

07.06.2024 - Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO (imetelstat) for the . Seite 1

Johna scarlettGeron corporation nasdaqDrug administrationGeron corporationChief executive

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. (BUSINESS WIRE) May 16, 2024

United statesCommunicationskristen kelleherAaron feingoldGeron corporationDrug administrationGeron corporation nasdaqEuropean unionNasdaq listing ruleAward planNobel prize winningNew drug applicationUnited states foodPrescription drug user fee actInvestor relationsCorporate communicationskristenBusiness wire

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS .

Johna scarlettGeron corporation nasdaqClinical developmentExchange commissionEuropean medicines agencyDrug administrationGeron corporationNew drug applicationChief executiveFast trackNobel prize winningPrescription drug user fee actMarketing authorization applicationPrivate securities litigation reform actMonths ended march

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAaron feingoldKristen kelleherEuropean unionDrug administrationCorporate communicationsGeron corporationGeron corporation nasdaqNasdaq listing ruleAward planNobel prize winningNew drug applicationUnited states foodPrescription drug user fee actInvestor relations